PBS Biotech

About PBS Biotech

Established in 2006 by Dr. Brian Lee and Gregory Zeikus, PBS Biotech operates from Camarillo, California, as a key equipment and services provider in the cell therapy sector. Dr. Lee, who also serves as CEO, brings over 25 years of extensive experience in biopharmaceutical R&D, bioprocess scale-up, and manufacturing from his time at major pharmaceutical companies like Amgen and Merck. This deep industry background directly informs the company's strategic focus on addressing critical manufacturing challenges for cell-based therapeutics.

PBS Biotech's business model is centered on the design, manufacture, and sale of single-use bioreactor systems, supplemented by process development and technical support services. The company serves a global clientele of academic institutions, biotechnology firms, and pharmaceutical companies engaged in the research, development, and commercialization of cell therapies. Revenue is generated primarily through a business-to-business (B2B) model involving direct sales of its bioreactor equipment and associated disposable components, often through custom quotes and supply agreements tailored to client needs.

The company's core product line features its proprietary Vertical-Wheel® technology, a distinct agitation mechanism designed to create a gentle and homogeneous mixing environment. This approach is particularly suited for cultivating shear-sensitive cell types, such as induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs), which are foundational to many next-generation regenerative medicines. The product portfolio offers a scalable path from early research to commercial production, with systems ranging from the PBS MINI for small-volume process development to the PBS 500 for clinical and commercial manufacturing applications. This scalability allows clients to streamline development and accelerate their time to market.

The company has successfully raised significant capital to fuel its growth, including a notable Series B funding round. These funds are allocated to expanding its product portfolio, enhancing process development services, and increasing manufacturing capacity to meet growing global demand. PBS Biotech is expanding its ISO 9001:2015 certified manufacturing facility to support over $100 million in annual revenue, signaling its readiness for its clients' scale-up to commercialization.